Notice of Results

RNS Number : 9623N

Shield Therapeutics PLC

15 August 2017

 

Shield Therapeutics plc

("Shield" or the "Group")

Notice of Results

London, UK, 15 August 2017: Shield Therapeutics (LSE: STX), a specialty pharmaceutical company focused on secondary care, announces it will report its interim results for the six months ended 30 June 2017 on Wednesday 20 September 2017.

Shield will host a presentation and conference call for analysts at 9.30am BST on the morning of the results in the Guildhall Room at 85 Gresham Street, London, EC2V 7NQ.

- Ends -

For further information please contact:

Shield Therapeutics plc		[phone]
Carl Sterritt, Chief Executive Officer Joanne Estell, Chief Financial Officer Karl Keegan, Director Corporate Development
Nominated Adviser and Joint Broker		[phone]
Liberum Capital Limited
Christopher Britton Steve Pearce Jonathan Wilkes-Green

Joint Broker		[phone]
Peel Hunt LLP
James Steel Alastair Rae
Oliver Jackson
Financial PR Advisor		[phone]
Consilium Strategic Communications
Mary-Jane Elliott Matthew Neal

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need.  Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com

 

END

 

 

NORBUGDIIXBBGRS